KIYATEC and Mayo Clinic collaborate to fight ovarian cancer
June 16, 2016 – GREENVILLE. KIYATEC Inc., a leader in emerging 3D ex vivo predictive cancer diagnostics, today announced a collaboration with Mayo Clinic to combine their complementary technology platforms for ovarian cancer clinical care.
Mayo Clinic is actively enrolling patients in a clinical study led by principal investigator John Weroha, M.D., in which patient-derived xenografts (PDX) generate living tumor samples specific to each enrolled ovarian cancer patient. The study assesses whether those samples can help determine which chemotherapy is most effective to treat that individual ovarian cancer patient should they become platinum resistant. A limitation of any PDX model is that it typically takes six to nine months before data is produced. For some patients that don’t respond at all to the initial treatment information is needed in just a few weeks, a challenge inherent to any clinical study of this sort – until now.
KIYATEC similarly uses living tumor samples specific to each ovarian cancer patient in its active research study with Greenville Health System (GHS), the first healthcare provider to partner with KIYATEC on this research. The difference is that KIYATEC uses its 3D cell culture platform to generate patient specific drug response prediction data in just 7 days. If the research collaboration is successful, KIYATEC’s technology would complement the Mayo approach and allow for more patients to be treated according to personalized drug response models.
“This significantly advances KIYATEC’s goal to validate the accuracy of our cell culture predictions against patient outcomes, the gold standard for these kinds of comparisons,” said Hal Crosswell, M.D., KIYATEC’s Chief Medical Officer.